Literature DB >> 21557041

Medical management of patients with brain tumors.

Amy A Pruitt1.   

Abstract

OPINION STATEMENT: Patients with brain tumors require meticulous attention to medical issues resulting from their disease or its therapy. The following specific issues are the ones most frequently arising in the purview of neurologists: (1) Vasogenic edema: Corticosteroids should be used in divided doses in the minimum amount required to control symptoms and should be tapered as quickly as possible. Some patients may require long-term steroid supplementation, and symptoms of adrenal insufficiency should be investigated with 8 AM: cortisol measurement and treated with appropriate repletion. (2) Seizures: Patients with brain tumors should receive antiepileptic drugs only if they have had seizures, and the drugs should be chosen to minimize cognitive effects and interactions with concurrently administered chemotherapy. Levetiracetam is an excellent choice for patients with partial seizures and is available both orally and parenterally. Lamotrigine is another reasonable choice but requires slow titration. (3) Venous thromboembolism: All brain tumor patients should receive perioperative venous thrombosis prophylaxis with compression boots and enoxaparin or dalteparin. Lifelong treatment with low molecular weight heparinoids or warfarin is required for those developing venous thromboembolism. (4) Other problems: Long-term survivors of brain tumors should be monitored indefinitely for cognitive problems, endocrine dysfunction, and development of secondary neoplasms. Modafinil can improve mood and attention impairments.

Entities:  

Year:  2011        PMID: 21557041     DOI: 10.1007/s11940-011-0132-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  50 in total

Review 1.  Corticosteroid supplementation for adrenal insufficiency.

Authors:  Douglas B Coursin; Kenneth E Wood
Journal:  JAMA       Date:  2002-01-09       Impact factor: 56.272

Review 2.  Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use.

Authors:  Richard H Mattson
Journal:  Rev Neurol Dis       Date:  2004

3.  Antiemetic properties of the antiepileptic drug levetiracetam.

Authors:  Jong Woo Lee; Edward B Bromfield; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

Review 4.  Thrombotic events in patients with cancer receiving antiangiogenesis agents.

Authors:  Maurizio Zangari; Louis M Fink; Francesca Elice; Fenghuang Zhan; Dorothy M Adcock; Guido J Tricot
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

5.  Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis.

Authors:  A T Chan; A Atiemo; L K Diran; G P Licholai; P McLaren Black; M A Creager; S Z Goldhaber
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

Review 6.  Thromboembolism in brain tumors.

Authors:  D C Walsh; A K Kakkar
Journal:  Curr Opin Pulm Med       Date:  2001-09       Impact factor: 3.155

Review 7.  [Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy].

Authors:  Gesine Meyer; Klaus Badenhoop
Journal:  Med Klin (Munich)       Date:  2003-04-25

8.  Safety of anticoagulation use and bevacizumab in patients with glioma.

Authors:  Phioanh Leia Nghiemphu; Richard M Green; Whitney B Pope; Albert Lai; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2008-04-24       Impact factor: 12.300

9.  A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.

Authors:  Jan Drappatz; Eric T Wong; David Schiff; Santosh Kesari; Tracy T Batchelor; Lisa Doherty; Debra Conrad Lafrankie; Naren Ramakrishna; Stephanie Weiss; Sharon T Smith; Abigail Ciampa; Jennifer Zimmerman; Louis Ostrowsky; Karly David; Andrew Norden; Loretta Barron; Christine Sceppa; Peter M Black; Patrick Y Wen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-29       Impact factor: 7.038

10.  Chronic health conditions in adult survivors of childhood cancer.

Authors:  Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 176.079

View more
  8 in total

Review 1.  Psychopharmacology in psycho-oncology.

Authors:  Rosangela Caruso; Luigi Grassi; Maria Giulia Nanni; Michelle Riba
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

Review 2.  Treating glioblastoma in the elderly.

Authors:  Jaime Gállego Pérez-Larraya; Jean-Yves Delattre
Journal:  CNS Oncol       Date:  2012-11

Review 3.  Management of elderly patients with gliomas.

Authors:  Jaime Gállego Pérez-Larraya; Jean-Yves Delattre
Journal:  Oncologist       Date:  2014-10-23

4.  Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.

Authors:  Katherine B Peters; Miranda J West; Whitney E Hornsby; Emily Waner; April D Coan; Frances McSherry; James E Herndon; Henry S Friedman; Annick Desjardins; Lee W Jones
Journal:  J Neurooncol       Date:  2014-08-13       Impact factor: 4.130

5.  Steroid management in newly diagnosed glioblastoma.

Authors:  Mariel B Deutsch; Katherine S Panageas; Andrew B Lassman; Lisa M Deangelis
Journal:  J Neurooncol       Date:  2013-03-06       Impact factor: 4.130

6.  Incidence, risk factors and outcomes of seizures occurring after craniotomy for primary brain tumor resection.

Authors:  Hasan M Al-Dorzi; Abdullah A Alruwaita; Bothaina O Marae; Bushra S Alraddadi; Hani M Tamim; Ahmad Ferayan; Yaseen M Arabi
Journal:  Neurosciences (Riyadh)       Date:  2017-04       Impact factor: 0.906

7.  The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.

Authors:  Hao Bai; Liwen Xiong; Baohui Han
Journal:  Onco Targets Ther       Date:  2017-04-27       Impact factor: 4.147

8.  Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases.

Authors:  Yayi He; Wenwen Sun; Yan Wang; Shengxiang Ren; Xuefei Li; Jiayu Li; Christopher J Rivard; Caicun Zhou; Fred R Hirsch
Journal:  Onco Targets Ther       Date:  2016-04-21       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.